| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1177/107327480701400203 |
| P698 | PubMed publication ID | 17387295 |
| P2093 | author name string | Neil A Fenske | |
| L Frank Glass | |||
| Connie A Keehn | |||
| Galina Shistik | |||
| Iriana P Belongie | |||
| P2860 | cites work | Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results | Q28300282 |
| Folliculotropic mycosis fungoides with central nervous system involvement: demonstration of tumor clonality in intrafollicular T cells using laser capture microdissection. | Q30886315 | ||
| Cutaneous T-cell lymphoma and human immunodeficiency virus infection: 2 cases and a review of the literature | Q33608278 | ||
| Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma | Q33935031 | ||
| The cutaneous T cell lymphoma, mycosis fungoides, is a human T cell lymphotropic virus-associated disease. A study of 50 patients | Q34199889 | ||
| Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome). | Q34333859 | ||
| WHO-EORTC classification for cutaneous lymphomas | Q34391006 | ||
| Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas | Q34470582 | ||
| The pathogenesis of mycosis fungoides | Q34547650 | ||
| Granulomatous slack skin: treatment with extensive surgery and review of the literature | Q35138341 | ||
| Topical carmustine (BCNU) in the treatment of mycosis fungoides | Q35612021 | ||
| Ketron-Goodman disease, Woringer-Kolopp disease, and pagetoid reticulosis | Q36022879 | ||
| Classification of cutaneous T-cell lymphoma: from Alibert to WHO-EORTC. | Q36367910 | ||
| On the diagnosis of erythrodermic cutaneous T-cell lymphoma | Q36367915 | ||
| Standard and experimental therapy in cutaneous T-cell lymphomas | Q36367929 | ||
| Biological insights into the pathogenesis of cutaneous T-cell lymphomas (CTCL). | Q36413638 | ||
| EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. | Q36436109 | ||
| Mycosis fungoides and sezary syndrome: an update | Q36562224 | ||
| Sézary syndrome: diagnosis, prognosis, and critical review of treatment options | Q37850441 | ||
| Interferons in the treatment of skin disease | Q38163893 | ||
| Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Definition of three distinctive prognostic groups | Q39714882 | ||
| Cytologic transformation in cutaneous T cell lymphoma: a clinicopathologic entity associated with poor prognosis | Q39724079 | ||
| Cutaneous T cell lymphoma: mycosis fungoides, Sézary syndrome, and other variants | Q40282384 | ||
| Hypopigmented variant of mycosis fungoides: demography, histopathology, and treatment of seven cases | Q40526189 | ||
| Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome | Q40566975 | ||
| Follicular mycosis fungoides. A histopathologic analysis of nine cases | Q40672974 | ||
| Circulating Sezary cells in hospitalized dermatology patients | Q40689861 | ||
| Lung involvement in scleroderma | Q40697298 | ||
| T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections | Q40787633 | ||
| The role of recombinant interferon alfa-2a in the therapy of cutaneous T-cell lymphomas | Q40809016 | ||
| Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution | Q41262862 | ||
| Mycosis fungoides in relation to environmental exposures and immune response: a case-control study | Q41327858 | ||
| Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients | Q41612139 | ||
| Pagetoid reticulosis (Woringer-Kolopp disease): an immunophenotypic, molecular, and clinicopathologic study. | Q41737636 | ||
| Granulomatous slack skin. Report of three patients with an updated review of the literature. | Q42458382 | ||
| Cutaneous malignancies and metastatic squamous cell carcinoma following topical therapies for mycosis fungoides | Q42525019 | ||
| Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sézary syndrome | Q43543686 | ||
| Cutaneous T-cell lymphoma and human immunodeficiency virus. The spectrum broadens | Q43722980 | ||
| Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma | Q43922982 | ||
| Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox | Q44083649 | ||
| Optimizing bexarotene therapy for cutaneous T-cell lymphoma | Q44194042 | ||
| D'emblee type of mycosis fungoides of head and neck | Q44390810 | ||
| Possible role of Epstein-Barr virus infection in cutaneous T-cell lymphomas | Q44411258 | ||
| Total skin electron beam irradiation for cutaneous T-cell lymphoma (mycosis fungoides). | Q44604779 | ||
| Histologic assessment of lymph nodes in mycosis fungoides/Sézary syndrome (cutaneous T-cell lymphoma): clinical correlations and prognostic import of a new classification system | Q45008356 | ||
| Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream | Q45251626 | ||
| Identification of herpes simplex virus DNA and lack of human herpesvirus-8 DNA in mycosis fungoides | Q45730659 | ||
| Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma. | Q52054622 | ||
| Clinical features associated with transformation of cerebriform T-cell lymphoma to a large cell process. | Q53506701 | ||
| Cytomegalovirus seropositivity is significantly associated with mycosis fungoides and Sézary syndrome. | Q55239670 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 102-111 | |
| P577 | publication date | 2007-04-01 | |
| P1433 | published in | Cancer Control | Q15724614 |
| P1476 | title | The diagnosis, staging, and treatment options for mycosis fungoides | |
| P478 | volume | 14 |
| Q37378472 | Atopic disease and risk of non-Hodgkin lymphoma: an InterLymph pooled analysis |
| Q24629558 | Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL) |
| Q37288403 | Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas |
| Q37237464 | Ectopic expression of B-lymphoid kinase in cutaneous T-cell lymphoma |
| Q40624542 | First treatment of mycosis fungoides by total skin electron beam (TSEB) therapy in Greece |
| Q37509450 | Hypopigmented mycosis fungoides: a review of its clinical features and pathophysiology |
| Q36977648 | Mycosis fungoides and Sézary syndrome: clinical, histopathological and immunohistochemical review and update |
| Q33835514 | Mycosis fungoides presenting as symmetric concentric patches mimicking figurate erythema. |
| Q37409523 | Mycosis fungoides staged by 18F-flurodeoxyglucose positron emission tomography/computed tomography: Case report and review of literature |
| Q42112667 | Mycosis fungoides: Positron emission tomography/computed tomography in staging and monitoring the effect of therapy |
| Q38014823 | Recurrence of mycosis fungoides on multiple melanocytic nevi: a case report and review of the literature. |
| Q34400497 | Reticulate dermatoses |
| Q34100988 | Thymocyte selection-associated high mobility group box gene (TOX) is aberrantly over-expressed in mycosis fungoides and correlates with poor prognosis |
| Q35939690 | Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects |
Search more.